Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Survey: Oncologists Show Support For Erbitux Uptake Based On KRAS Test

This article was originally published in The Pink Sheet Daily

Executive Summary

Approach could encourage front-line Erbitux use in some colorectal patients, Rodman & Renshaw finds after oncologist survey.

You may also be interested in...



Leaner Genmab A More Likely Buy For GSK?

Staff cutbacks, dropped programs, and out-licensing plans unveiled.

Leaner Genmab A More Likely Buy For GSK?

Staff cutbacks, dropped programs, and out-licensing plans unveiled.

Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls

$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel